Trial Profile
Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study to Evaluate the Safety and Tolerability of S-1226 Administered by Nebulization in Normal Health Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2018
Price :
$35
*
At a glance
- Drugs Carbon dioxide/perflubron (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors SolAeroMed
- 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
- 04 Aug 2015 New trial record